Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.

Trial Details

NCT ID
NCT07361224
Phase
PHASE1
Sponsor
Tel-Aviv Sourasky Medical Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • rhDNase I
Locations (sample)
  • Tel Aviv, Israel|32.08088,34.78057

Key Eligibility Criteria

  • Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.
  • Large B-Cell lymphoma treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)
  • Stable Disease or Progressive Disease confirmed by PET-CT on the day of lymphodepletion
  • Capable of giving signed informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →